MK-0859
Total Payments
$8.0M
Transactions
1,628
Doctors
17
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $11,337 | 4 | 1 |
| 2019 | $1.7M | 448 | 0 |
| 2018 | $2.3M | 561 | 2 |
| 2017 | $4.1M | 615 | 16 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.0M | 1,569 | 99.1% |
| Travel and Lodging | $60,261 | 28 | 0.7% |
| Consulting Fee | $15,000 | 9 | 0.2% |
| Food and Beverage | $873.25 | 22 | 0.0% |
Payments by Type
Research
$8.0M
1,569 transactions
General
$76,134
59 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease. | Merck Sharp & Dohme Corporation | $7.7M | 1 |
| Understanding the Determinants of Change in HDL Function in High-Risk Multi-Ethnic Populations and in Response to Anacetrapib Therapy | Merck Sharp & Dohme Corporation | $252,141 | 0 |
| A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients with Coronary Heart Disease CHD or CHD Risk-Equivalent Disease | Merck Sharp & Dohme Corporation | $16,067 | 0 |
| An Off-Drug Follow-Up Study of Women of Child-Bearing Potential who Previously Received Multiple Oral Doses of MK-0859 | Merck Sharp & Dohme Corporation | $5,044 | 0 |
| An Off-Drug Follow-Up Study of Women of Child-Bearing Potential and Off-Drug Follow-Up Pharmacokinetic Study of Men and Women who Previously Received Multiple OralDoses of MK-0859 | Merck Sharp & Dohme Corporation | $3,957 | 0 |
| A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medications in Patients with Heterozygous Familial Hypercholesterolemia REALIZE | Merck Sharp & Dohme Corporation | $194.99 | 0 |
Top Doctors Receiving Payments for MK-0859
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Albuquerque, NM | $8.0M | 1,567 |
| , MD | Cardiovascular Disease | Boston, MA | $33,801 | 18 |
| , MD | Cardiovascular Disease | Boston, MA | $17,385 | 9 |
| , MD | Cardiovascular Disease | Boston, MA | $9,878 | 5 |
| , M.D | Cardiovascular Disease | Beverly Hills, CA | $3,900 | 2 |
| , MD | Internal Medicine | Washington, DC | $3,629 | 3 |
| , M.D | Internal Medicine | New York, NY | $3,335 | 3 |
| , MD | Internal Medicine | Boston, MA | $3,082 | 2 |
| , M.D | Internal Medicine | San Antonio, TX | $1,000 | 1 |
| , M.D | Internal Medicine | Tacoma, WA | $1,000 | 1 |
| , MD | Family Medicine | Evansville, IN | $1,000 | 1 |
| Kenneth Lasseter | — | Hialeah, FL | $1,000 | 1 |
| , MD | Internal Medicine | Philadelphia, PA | $598.59 | 5 |
| , MD | Cardiovascular Disease | Boston, MA | $167.01 | 2 |
| Michael Davidson | Cardiovascular Disease | Chicago, IL | $64.88 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $64.88 | 2 |
| , MD | Cardiovascular Disease | Boston, MA | $64.88 | 2 |
| , MD | Cardiovascular Disease | Rochester, NY | $64.88 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $8.0M
- Total Doctors 17
- Transactions 1,628
About MK-0859
MK-0859 is a drug associated with $8.0M in payments to 17 healthcare providers, recorded across 1,628 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $11,337 was paid across 4 transactions to 1 doctors.
The most common payment nature for MK-0859 is "Unspecified" ($8.0M, 99.1% of total).
MK-0859 is associated with 6 research studies, including "HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease." ($7.7M).